These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19369827)

  • 1. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
    Kato H; Ito E; Shi W; Alajez NM; Yue S; Lee C; Chan N; Bhogal N; Coackley CL; Vines D; Green D; Waldron J; Gullane P; Bristow R; Liu FF
    Clin Cancer Res; 2010 Feb; 16(3):898-911. PubMed ID: 20103674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
    Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
    Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
    Chan M; Gravel M; Bramoullé A; Bridon G; Avizonis D; Shore GC; Roulston A
    Cancer Res; 2014 Nov; 74(21):5948-54. PubMed ID: 25145669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
    Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
    Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
    Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
    J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
    Saif MW; von Borstel R
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):136-42. PubMed ID: 16187114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
    Stover TC; Sharma A; Robertson GP; Kester M
    Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
    Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
    Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
    Olesen UH; Christensen MK; Björkling F; Jäättelä M; Jensen PB; Sehested M; Nielsen SJ
    Biochem Biophys Res Commun; 2008 Mar; 367(4):799-804. PubMed ID: 18201551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
    Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.
    Cerna D; Li H; Flaherty S; Takebe N; Coleman CN; Yoo SS
    J Biol Chem; 2012 Jun; 287(26):22408-17. PubMed ID: 22570471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.